Protein Kinase Inhibitors: all 15,147 studies that test it

Page 34 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)CompletedNCT03845517Phase 2Results posted
• A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant CancersCompletedNCT03843775Phase 1/2Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT03843125Phase 3Results posted
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results posted
• A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.CompletedNCT03840200Phase 1Results posted
• Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast CancerCompletedNCT03839823Phase 2Results posted
• Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT03836209Phase 2Results posted
• Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaActive, not recruitingNCT03834961Phase 2Results posted
• A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for ResectionCompletedNCT03834740Early Phase 1Results posted
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)TerminatedNCT03834220Phase 2Results posted
• Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)TerminatedNCT03833427Phase 1Results posted
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03831932Phase 1/2Results posted
• Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationCompletedNCT03829410Phase 1/2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedNCT03829332Phase 3Results posted
• Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)CompletedNCT03829319Phase 3Results posted
• Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal CancerCompletedNCT03828799Phase 1/2Results posted
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2Results posted
• Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03827798Phase 2Results posted
• Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis ComplexCompletedNCT03826628Phase 2/3Results posted
• A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibTerminatedNCT03823378Phase 2Results posted
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerCompletedNCT03822468Phase 2Results posted
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)TerminatedNCT03822117Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)CompletedNCT03820986Phase 3Results posted
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT03820726Phase 3Results posted
• Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03811912Phase 2Results posted
• A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy ParticipantsCompletedNCT03811834Phase 1Results posted
• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerActive, not recruitingNCT03807778Phase 1Results posted
• Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsTerminatedNCT03805841Phase 2Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia AreataCompletedNCT03800979Phase 4Results posted
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisCompletedNCT03796676Phase 3Results posted
• Study of PF 04965842 Effect on MATE1/2K Activity in Healthy ParticipantsCompletedNCT03796182Phase 1Results posted
• IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaCompletedNCT03795610Phase 2Results posted
• Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisCompletedNCT03793439Phase 1Results posted
• Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)CompletedNCT03792256Phase 1Results posted
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaActive, not recruitingNCT03789240Phase 2Results posted
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingNCT03787680Phase 2Results posted
• Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With LymphomasTerminatedNCT03786926Phase 1Results posted
• Abemaciclib and Nivolumab for Subjects With Hepatocellular CarcinomaTerminatedNCT03781960Phase 2Results posted
• An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1Results posted
• Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingNCT03778229Phase 2Results posted
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results posted
• Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast CancerCompletedNCT03774472Phase 1/2Results posted
• Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
• A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic ArthritisCompletedNCT03773978Phase 3Results posted
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsTerminatedNCT03773302Phase 3Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• Study of Peposertib in Combination With Capecitabine and RT in Rectal CancerCompletedNCT03770689Phase 1/2Results posted
• A Study of LY3405105 in Participants With Advanced CancerTerminatedNCT03770494Phase 1Results posted
• Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaCompletedNCT03770000Phase 1/2Results posted
• Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)TerminatedNCT03768505Phase 2Results posted
• MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1Results posted
• GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedNCT03765983Phase 2Results posted
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedNCT03764618Phase 3Results posted
• A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Phase 3Results posted
• A Study of PRN1008 in Patients With PemphigusTerminatedNCT03762265Phase 3Results posted
• ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)TerminatedNCT03759340Phase 2Results posted
• Efficacy & Safety of TD-1473 in Ulcerative ColitisTerminatedNCT03758443Phase 2/3Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)CompletedNCT03745989Phase 1Results posted
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745651Phase 3Results posted
• Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745638Phase 3Results posted
• A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedNCT03744715Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCATerminatedNCT03742973Phase 2Results posted
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaCompletedNCT03742258Phase 1Results posted
• Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsTerminatedNCT03740100Phase 2Results posted
• A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03738397Phase 3Results posted
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03735875Phase 1/2Results posted
• A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedNCT03734016Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic DermatitisCompletedNCT03733301Phase 3Results posted
• PF-06651600 for the Treatment of Alopecia AreataCompletedNCT03732807Phase 2/3Results posted
• Altering Memories That Increase Risk of Relapse in Alcohol Use DisordersCompletedNCT03732248Phase 1Results posted
• A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)CompletedNCT03730012Phase 1/2Results posted
• Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand EczemaCompletedNCT03728504Phase 2Results posted
• Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaCompletedNCT03727880Phase 2Results posted
• Hepatic Impairment Study for Lorlatinib in Cancer PatientsTerminatedNCT03726333Phase 1Results posted
• Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.CompletedNCT03725722Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell ArteritisCompletedNCT03725202Phase 3Results posted
• Study of Avelumab-M3814 CombinationsCompletedNCT03724890Phase 1Results posted
• Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionActive, not recruitingNCT03722407Phase 2Results posted
• Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedNCT03721965Phase 1/2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 3Results posted
• M6620 (VX-970) in Selected Solid TumorsCompletedNCT03718091Phase 2Results posted
• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03717415Phase 1/2Results posted
• A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo SubjectsCompletedNCT03715829Phase 2Results posted
• Compassionate Use Study of Tenalisib (RP6530)CompletedNCT03711604Phase 1/2Results posted
• Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)CompletedNCT03711578Phase 2Results posted
• A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue SarcomaTerminatedNCT03711279Phase 2Results posted
• Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerCompletedNCT03711058Phase 1/2Results posted
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsCompletedNCT03709680Phase 2Results posted
• A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid TumorsCompletedNCT03708211Phase 1Results posted
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerActive, not recruitingNCT03706365Phase 2/3Results posted
• Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung CancerCompletedNCT03704688Phase 1/2Results posted
• Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian CancerCompletedNCT03704467Phase 1Results posted
• A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast CancerCompletedNCT03703466Phase 2Results posted

← Protein Kinase Inhibitors overview